Avalon globocare expands its cellular immuno-oncology platform with the addition of novel chimeric antigen receptor-natural killer (car-nk) cell therapies

Freehold, n.j., feb. 14, 2022 (globe newswire) -- avalon globocare corp. (nasdaq: avco), a leading global developer of cell-based technologies and therapeutics, announced today that the company is expanding its cellular immuno-oncology program with the addition of novel chimeric antigen receptor – natural killer (car-nk) cell therapies.
AVCO Ratings Summary
AVCO Quant Ranking